JP2005531614A - ワクチン組成物 - Google Patents

ワクチン組成物 Download PDF

Info

Publication number
JP2005531614A
JP2005531614A JP2004512791A JP2004512791A JP2005531614A JP 2005531614 A JP2005531614 A JP 2005531614A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2004512791 A JP2004512791 A JP 2004512791A JP 2005531614 A JP2005531614 A JP 2005531614A
Authority
JP
Japan
Prior art keywords
vesicle
meningococcal
strain
vesicles
bactericidal activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004512791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531614A5 (cg-RX-API-DMAC7.html
Inventor
バーベラ,モラレス,ラモン,ファウスティノ
デスモン,ピエール,ミッシェル
アルヴァレス,フランシスコ,ヘサス ドミンゲス
プールマン,ジャン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
インスティチュート フィンレイ,セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, インスティチュート フィンレイ,セントロ デ インヴェスティゲション−プロダクシオン デ スエロス イ ヴァキュナス filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2005531614A publication Critical patent/JP2005531614A/ja
Publication of JP2005531614A5 publication Critical patent/JP2005531614A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2004512791A 2002-06-13 2003-06-10 ワクチン組成物 Pending JP2005531614A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0213622.4A GB0213622D0 (en) 2002-06-13 2002-06-13 Vaccine Corporation
PCT/EP2003/006094 WO2003105890A2 (en) 2002-06-13 2003-06-10 Vaccine composition

Publications (2)

Publication Number Publication Date
JP2005531614A true JP2005531614A (ja) 2005-10-20
JP2005531614A5 JP2005531614A5 (cg-RX-API-DMAC7.html) 2006-07-27

Family

ID=9938532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004512791A Pending JP2005531614A (ja) 2002-06-13 2003-06-10 ワクチン組成物

Country Status (20)

Country Link
US (1) US20060110412A1 (cg-RX-API-DMAC7.html)
EP (1) EP1565211A2 (cg-RX-API-DMAC7.html)
JP (1) JP2005531614A (cg-RX-API-DMAC7.html)
KR (1) KR20050049431A (cg-RX-API-DMAC7.html)
CN (1) CN100387298C (cg-RX-API-DMAC7.html)
AR (1) AR040204A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003236734A1 (cg-RX-API-DMAC7.html)
BR (1) BR0311777A (cg-RX-API-DMAC7.html)
CA (1) CA2488782A1 (cg-RX-API-DMAC7.html)
CL (1) CL2003001192A1 (cg-RX-API-DMAC7.html)
CU (1) CU23552A1 (cg-RX-API-DMAC7.html)
GB (1) GB0213622D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04012568A (cg-RX-API-DMAC7.html)
NO (1) NO20050132L (cg-RX-API-DMAC7.html)
NZ (1) NZ560766A (cg-RX-API-DMAC7.html)
PE (1) PE20040562A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005100509A (cg-RX-API-DMAC7.html)
UY (1) UY27843A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003105890A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200409547B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドSanofi Pasteur Limited 免疫原性組成物

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP5792920B2 (ja) * 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
SI2268618T1 (sl) 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
HUE040658T2 (hu) * 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
CA2810971C (en) 2010-09-10 2020-11-03 Novartis Ag Developments in meningococcal outer membrane vesicles
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
MX2014008988A (es) 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
WO2013132040A2 (en) 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
CN116670157A (zh) * 2020-10-23 2023-08-29 Omvax公司 用于抗淋病奈瑟球菌的疫苗接种的组合物和方法
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510169A (ja) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン, インコーポレイテッド B型髄膜炎菌性ポーリンおよびH.influenzae多糖体を含む免疫原性結合体
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
MXPA03000822A (es) * 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511275A (ja) * 2008-02-01 2011-04-07 サノフィ パストゥール リミテッド 診断的アッセイ
JP2013507354A (ja) * 2009-10-08 2013-03-04 イオン メディックス インコーポレイテッド 室内空気由来細胞外ベシクルを含む組成物及びその用途
JP2016104776A (ja) * 2009-12-22 2016-06-09 サノフィ パストゥール リミテッドSanofi Pasteur Limited 免疫原性組成物

Also Published As

Publication number Publication date
UY27843A1 (es) 2003-12-31
CA2488782A1 (en) 2003-12-24
BR0311777A (pt) 2005-03-29
MXPA04012568A (es) 2005-09-21
WO2003105890A2 (en) 2003-12-24
KR20050049431A (ko) 2005-05-25
PE20040562A1 (es) 2004-10-19
RU2005100509A (ru) 2006-06-10
AU2003236734A1 (en) 2003-12-31
CN100387298C (zh) 2008-05-14
EP1565211A2 (en) 2005-08-24
CU23552A1 (es) 2010-07-20
NO20050132L (no) 2005-02-11
US20060110412A1 (en) 2006-05-25
AR040204A1 (es) 2005-03-16
ZA200409547B (en) 2006-07-26
NO20050132D0 (no) 2005-01-11
CL2003001192A1 (es) 2005-01-07
GB0213622D0 (en) 2002-07-24
CN1668329A (zh) 2005-09-14
NZ560766A (en) 2009-09-25
WO2003105890A3 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
CN100387298C (zh) 疫苗组合物
TWI360424B (en) Vaccine
JP5275983B2 (ja) ワクチン
US20050244436A1 (en) Combination Neisserial compositions
US20170209562A1 (en) Immunogenic composition
Pinto et al. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups
EP1572729B1 (en) Mutant frpb protein and refolding method
EP1532168A2 (en) Method for refolding neisserial nspa protein
RU2359696C2 (ru) Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий
AU2016228231A1 (en) Combination Neisserial compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101102